COVID-PACT is a multicenter, randomized, open-label, 2 x 2 factorial design trial of full-dose anticoagulation vs. standard-dose prophylactic anticoagulation and antiplatelet therapy vs. no antiplatelet therapy on the risk of venous or arterial thrombotic events in ICU patients with COVID-19. Study patients will be followed until their 28th day or hospital discharge, whichever comes first.
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
MAIN RESULTS PRESENTATIONS
COVID-PACT Primary Results (Berg, ESC 2022)
COVID-PACT on ClinicalTrials.gov
CONTACT US about COVID-PACT